Literature DB >> 2592909

Apparent effect of immune serum globulin prophylaxis in the military on viral hepatitis incidence in the civilian population in Israel.

M S Green1, C Block.   

Abstract

Since 1969, extensive use of immune serum globulin in the Israel Defence Force for prophylaxis against hepatitis A virus (HAV) infection has produced a sharp decline in the incidence of the disease. However, it is not clear whether this policy has affected the susceptibility of Israeli adults to HAV infection. In this study, we examined the effect of the immunisation policy on the incidence of hepatitis A virus infection in the civilian population in the 15-44 year age group, which includes all those who have completed compulsory military service since vaccination was introduced. The incidence of viral hepatitis in the Jewish civilian population aged 15-44 increased by approximately 50% 3-4 years after the implementation of the immunisation policy. This rise was not seen in the non-Jewish population of the same age nor among Jews aged 45-64. These findings strongly suggest that the immunisation policy in the military prevents both clinical and sub-clinical disease, but has had the effect of producing more susceptible people at an older age in the civilian population.

Entities:  

Mesh:

Year:  1989        PMID: 2592909      PMCID: PMC1052823          DOI: 10.1136/jech.43.2.187

Source DB:  PubMed          Journal:  J Epidemiol Community Health        ISSN: 0143-005X            Impact factor:   3.710


  11 in total

1.  Infectious hepatitis. Studies on the effect of gamma globulin and on the incidence of inapparent infection.

Authors:  S KRUGMAN; R WARD; J P GILES; A M JACOBS
Journal:  JAMA       Date:  1960-10-15       Impact factor: 56.272

2.  Infectious hepatitis; length of protection by immune serum globulin (gamma globulin) during epidemics.

Authors:  J STOKES; J A FARQUHAR; M E DRAKE; R B CAPPS; C S WARD; A W KITTS
Journal:  J Am Med Assoc       Date:  1951-10-20

3.  Viral hepatitis: enzyme assays and serologic procedures in the study of an epidemic.

Authors:  J Rakela; E Nugent; J W Mosley
Journal:  Am J Epidemiol       Date:  1977-12       Impact factor: 4.897

4.  Viral hepatitis abroad. Incidence in Catholic missionaries.

Authors:  R D Woodson; K M Cahill
Journal:  JAMA       Date:  1972-02-28       Impact factor: 56.272

5.  Immunoprophylaxis of viral hepatitis.

Authors:  L B Seeff; J H Hoofnagle
Journal:  Gastroenterology       Date:  1979-07       Impact factor: 22.682

6.  Pre-exposure prophylaxis of viral hepatitis with immune serum globulin in an endemic area. A trial in field units of the Israel Defence Forces.

Authors:  J D Kark
Journal:  Scand J Infect Dis       Date:  1983

7.  Type B and non-B viral hepatitis in Jerusalem.

Authors:  S G Sandler; D Shouval; M Marcus; M Eliakim
Journal:  Bull World Health Organ       Date:  1976       Impact factor: 9.408

8.  Epidemiological features of acute viral hepatitis among the Israeli Defence Forces, 1977-83.

Authors:  H Matzkin
Journal:  J Infect       Date:  1987-05       Impact factor: 6.072

9.  The three-year incidence of non-B viral hepatitis morbidity in a controlled trial of pre-exposure immune serum globulin prophylaxis.

Authors:  J D Kark; E Witztum; H Mazkin; E Nili; Y L Danon
Journal:  Infection       Date:  1984 Jul-Aug       Impact factor: 3.553

10.  Efficacy of immune serum globulin in an outbreak of hepatitis A virus infection in adults.

Authors:  M S Green; K Dotan
Journal:  J Infect       Date:  1988-11       Impact factor: 6.072

View more
  1 in total

Review 1.  Clinical development of a new inactivated hepatitis A vaccine.

Authors:  E Vidor; B Fritzell; S Plotkin
Journal:  Infection       Date:  1996 Nov-Dec       Impact factor: 3.553

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.